Patient and disease characteristics (N = 83)
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 58 (19-85) |
| Males | 56 (67) |
| Disease | |
| B-cell lymphoma | 40 (48) |
| B-cell acute lymphoblastic leukemia | 37 (45) |
| Multiple myeloma | 6 (7) |
| >3 prior lines of therapy | 45 (54) |
| Baseline cytopenia | 73 (88) |
| CAR construct* | |
| Axicabtagene ciloleucel | 30 (36) |
| Tisagenlecleucel | 10 (12) |
| 19-28z CAR T cells | 37 (45) |
| Anti-BCMA CAR T cells | 6 (7) |
| Lymphodepleting chemotherapy | |
| Fludarabine and cyclophosphamide | 51 (61) |
| High-dose cyclophosphamide | 31 (37) |
| Bendamustine | 1 (1) |
| CRS grade | |
| 0 | 13 (16) |
| 1-2 | 51 (61) |
| 3-4 | 19 (23) |
| ICANS grade | |
| 0 | 36 (43) |
| 1-2 | 17 (21) |
| 3-4 | 30 (36) |
| Prior autologous or allogeneic stem cell transplantation | 30 (37) |
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 58 (19-85) |
| Males | 56 (67) |
| Disease | |
| B-cell lymphoma | 40 (48) |
| B-cell acute lymphoblastic leukemia | 37 (45) |
| Multiple myeloma | 6 (7) |
| >3 prior lines of therapy | 45 (54) |
| Baseline cytopenia | 73 (88) |
| CAR construct* | |
| Axicabtagene ciloleucel | 30 (36) |
| Tisagenlecleucel | 10 (12) |
| 19-28z CAR T cells | 37 (45) |
| Anti-BCMA CAR T cells | 6 (7) |
| Lymphodepleting chemotherapy | |
| Fludarabine and cyclophosphamide | 51 (61) |
| High-dose cyclophosphamide | 31 (37) |
| Bendamustine | 1 (1) |
| CRS grade | |
| 0 | 13 (16) |
| 1-2 | 51 (61) |
| 3-4 | 19 (23) |
| ICANS grade | |
| 0 | 36 (43) |
| 1-2 | 17 (21) |
| 3-4 | 30 (36) |
| Prior autologous or allogeneic stem cell transplantation | 30 (37) |
Unless otherwise noted, data are n (%).
Patients with B-cell lymphoma received axicabtagene ciloleucel or tisagenlecleucel, patients with B-cell ALL received 19-28z CAR T cells, and patients with MM received anti-BCMA CAR T cells.